DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ramadoss, Nitya S. | ko |
dc.contributor.author | Schulman, Andrew D. | ko |
dc.contributor.author | Choi, Sei-hyun | ko |
dc.contributor.author | Rodgers, David T. | ko |
dc.contributor.author | Kazane, Stephanie A. | ko |
dc.contributor.author | Kim, Chan Hyuk | ko |
dc.contributor.author | Lawson, Brian R. | ko |
dc.contributor.author | Young, Travis S. | ko |
dc.date.accessioned | 2016-07-04T06:01:47Z | - |
dc.date.available | 2016-07-04T06:01:47Z | - |
dc.date.created | 2016-05-14 | - |
dc.date.created | 2016-05-14 | - |
dc.date.created | 2016-05-14 | - |
dc.date.issued | 2015-04 | - |
dc.identifier.citation | JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, v.137, no.16, pp.5288 - 5291 | - |
dc.identifier.issn | 0002-7863 | - |
dc.identifier.uri | http://hdl.handle.net/10203/209124 | - |
dc.description.abstract | The development of immunotherapies for multiple. myeloma is critical to provide new treatment Strategies to combat drug resistance. We report a bispecific antibody against B cell maturation antigen (BiFab-BCMA), which potently and specifically redirects 1 cells to lyse malignant multiple myeloma cells. BiFab-BCMA lysed target BCMA-positive cell lilies up to more potently than a CS1-targeting bispecific Antibody (BiFab-CS1) developed in an analogous fashion, Further, BiFab-BCMA robustly activated T cells in vitro and mediated rapid tumor regression in an orthotopic:xenograft model of multiple myeloma.. The in vitro :and in vivo activities of BiPab-BCMA are comparable to those of anti-BCMA chimeric antigen receptor T cell therapy CAR-T-BCMA), for which two clinical trials have recently:been initiated. A BCMA-targeted bispecific antibody presents a promising treatment option for multiple myeloma. | - |
dc.language | English | - |
dc.publisher | AMER CHEMICAL SOC | - |
dc.subject | SINGLE-CHAIN ANTIBODY | - |
dc.subject | IN-VIVO | - |
dc.subject | MONOCLONAL-ANTIBODY | - |
dc.subject | PLASMA-CELLS | - |
dc.subject | IMMUNOTHERAPY | - |
dc.subject | THERAPY | - |
dc.subject | TARGET | - |
dc.subject | CYTOTOXICITY | - |
dc.subject | RECEPTOR | - |
dc.subject | FUTURE | - |
dc.title | An Anti-B Cell Maturation Antigen Bispecific Antibody for Multiple Myeloma | - |
dc.type | Article | - |
dc.identifier.wosid | 000353931500012 | - |
dc.identifier.scopusid | 2-s2.0-84928749842 | - |
dc.type.rims | ART | - |
dc.citation.volume | 137 | - |
dc.citation.issue | 16 | - |
dc.citation.beginningpage | 5288 | - |
dc.citation.endingpage | 5291 | - |
dc.citation.publicationname | JOURNAL OF THE AMERICAN CHEMICAL SOCIETY | - |
dc.identifier.doi | 10.1021/jacs.5b01876 | - |
dc.contributor.localauthor | Kim, Chan Hyuk | - |
dc.contributor.nonIdAuthor | Ramadoss, Nitya S. | - |
dc.contributor.nonIdAuthor | Schulman, Andrew D. | - |
dc.contributor.nonIdAuthor | Choi, Sei-hyun | - |
dc.contributor.nonIdAuthor | Rodgers, David T. | - |
dc.contributor.nonIdAuthor | Kazane, Stephanie A. | - |
dc.contributor.nonIdAuthor | Lawson, Brian R. | - |
dc.contributor.nonIdAuthor | Young, Travis S. | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordPlus | SINGLE-CHAIN ANTIBODY | - |
dc.subject.keywordPlus | IN-VIVO | - |
dc.subject.keywordPlus | MONOCLONAL-ANTIBODY | - |
dc.subject.keywordPlus | PLASMA-CELLS | - |
dc.subject.keywordPlus | IMMUNOTHERAPY | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | TARGET | - |
dc.subject.keywordPlus | CYTOTOXICITY | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | FUTURE | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.